Invitrogen’s Q2 Revenue Rises 13 Percent as Profit Doubles | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen said Wednesday that its second-quarter revenue climbed 13 percent as R&D spending rose 11 percent and net income was up 108 percent.
 
Total receipts for the three months ended June 30, 2007 rose to $321.7 million from $285.4 million year over year.
 
Invitrogen’s Biodiscovery sales rose 10 percent to $223 million for the second quarter, while its Cell Culture Systems division saw revenue rise 20 percent to $99 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.